bluebird bio

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
January 23, 2018
Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
October 24, 2017
Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

[vc_row][vc_column][vc_column_text] Philadelphia-based Spark Therapeutics recently received unanimous backing from an FDA advisory panel for Luxturna™, a one-shot gene therapy treatment for biallelic RPE65-mediated inherited retinal dystrophy […]
August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
June 23, 2015
Kite Pharma & bluebird bio Announce Strategic Collaboration to Treat HPV-Associated Cancers

Kite Pharma & bluebird bio Announce Strategic Collaboration to Treat HPV-Associated Cancers

With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech […]
Contact Us